Internal Medicine, Endocrinology, Diabetes, & Metabolism · Houston, TX
NPI
1134224942
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
10837 Katy Fwy Ste 200
Houston, TX, 77079
Phone (713) 468-2122
Groups this clinician bills Medicare through
Medicare paid, 2024
$123K
2,904 services
Medicare patients, 2024
249
Average age 74
Drug cost, 2024
$5.8M
6,851 prescriptions
Company payments, 2025
$124K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel S Tung was code 99490 (chronic, principal, and transitional care management), 706 times for 80 patients. In total Daniel S Tung billed 2,904 services in 30 codes, and Medicare paid $123K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 706 | 80 | $47.98 | $34K |
| 99421 Office/Outpatient Services | Office | 483 | 17 | $11.39 | $5,503 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 323 | 179 | $12.21 | $3,942 |
| 99214 Office E&M - Established | Office | 306 | 182 | $91.59 | $28K |
| 99215 Office E&M - Established | Office | 149 | 120 | $124.02 | $18K |
| 99457 E&M - Miscellaneous | Office | 115 | 17 | $37.74 | $4,341 |
| 99454 E&M - Miscellaneous | Office | 109 | 17 | $34.99 | $3,814 |
| 95251 Test - Miscellaneous | Office | 82 | 51 | $26.44 | $2,168 |
| 93922 Duplex Scan - Extremity Arteries | Office | 82 | 41 | $60.12 | $4,929 |
| 82962 Clinical Chemistry | Office | 46 | 35 | $3.21 | $148 |
| 95250 Test - Miscellaneous | Office | 29 | 24 | $105.79 | $3,068 |
| G0506 Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 24 | 23 | $45.58 | $1,094 |
| 99204 Office E&M - New | Office | 24 | 24 | $122.87 | $2,949 |
| 76536 Ultrasound - Nonspecific | Office | 15 | 14 | $80.80 | $1,212 |
| 99205 Office E&M - New | Office | 15 | 15 | $129.65 | $1,945 |
By year: 2022 $91K for 2,318 services; 2023 $104K for 1,762 services; 2024 $123K for 2,904 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 46 | 35 | $3.21 | $148 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel S Tung prescribed most often to Medicare patients was Ozempic (Semaglutide), with 641 prescriptions and refills. In total Daniel S Tung wrote 6,851 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 641 | 1,226 | 158 | $1.1M |
| Levothyroxine Sodium Generic | 470 | 1,324 | 156 | $4,770 |
| Atorvastatin Calcium Generic | 459 | 1,313 | 155 | $4,531 |
| Mounjaro Tirzepatide | 435 | 566 | 87 | $590K |
| Rosuvastatin Calcium Generic | 419 | 1,221 | 143 | $5,456 |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 300 | 660 | 78 | $362K |
| Metformin Hcl Generic | 289 | 830 | 103 | $1,793 |
| Pioglitazone Hcl Generic | 251 | 703 | 81 | $3,659 |
| Farxiga Dapagliflozin Propanediol | 215 | 504 | 56 | $265K |
| Synthroid Levothyroxine Sodium | 175 | 499 | 46 | $16K |
| Tresiba Flextouch U-100 Insulin Degludec | 163 | 403 | 57 | $80K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 140 | 373 | 61 | $17K |
| Jardiance Empagliflozin | 112 | 235 | 34 | $134K |
| Methimazole Generic | 107 | 224 | 24 | $655 |
| Cequr Simplicity Bolus Insulin Pump, 200 Unit | 99 | 184 | 29 | $86K |
Brand drugs: 3,797 claims; generic drugs: 2,516 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel S Tung $124K ($124K in general payments such as food, travel and fees) from 29 companies. The largest payer was Lilly USA, LLC with $81K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 168 | $81K |
| Novo Nordisk Inc NVO | 41 | $23K |
| Corcept Therapeutics CORT | 34 | $13K |
| CeQur Corporation | 2 | $1,995 |
| Beta Bionics, Inc. BBNX | 13 | $685 |
| Amgen Inc. AMGN | 18 | $602 |
| Recordati_rare_diseases_inc. | 16 | $452 |
| Madrigal Pharmaceuticals MDGL | 9 | $442 |
| Neurocrine BioSciences, Inc. NBIX | 7 | $421 |
| Ascensia Diabetes Care Us Inc. | 13 | $373 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.